$XGN News

Exagen (XGN) Q2 2026 Earnings Call Transcript

Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution

TD Cowen Maintains Buy on Exagen, Raises Price Target to $10

Exagen Inc. 2026 Q2 - Results - Earnings Call Presentation

B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12

BTIG Maintains Buy on Exagen, Raises Price Target to $9

Exagen: The Path To Profitability Just Became More Credible

Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability

Exagen Q2 Earnings Call Highlights

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Exagen (NASDAQ:XGN) Beats Q2 Estimates and Raises Full-Year Guidance

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est

Exagen Inc. to Participate in Upcoming Investor Conference

Exagen to Announce Second Quarter Financial Results on August 4, 2026

Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8

Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus